inogatran and glycine
inogatran has been researched along with glycine in 35 studies
Research
Studies (35)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (71.43) | 18.2507 |
| 2000's | 10 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, L; Mattsson, C; Mehta, JL; Nichols, WW; Saldeen, TG; Teger-Nilsson, AC | 1 |
| Grip, L; Mattsson, C; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD | 1 |
| Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC | 1 |
| Andersen, K; Dellborg, M; Emanuelsson, H; Grip, L; Swedberg, K | 1 |
| Verstraete, M | 1 |
| Bylund, R; Eriksson, U; Gustafsson, D; Gyzander, E; Teger-Nilsson, AC | 1 |
| Talley, JD | 1 |
| Heickendorff, L; Lüscher, MS; Ravkilde, J; Thygesen, K | 1 |
| Deinum, J; Elg, M; Gustafsson, D | 1 |
| Carlsson, S; Eriksson, BI; Halvarsson, M; Mattsson, C; Risberg, B | 1 |
| Antman, EM | 1 |
| Deschenes, I; DiMaio, J; Finkle, CD; Leblond, L; St Pierre, A; Winocour, PD | 1 |
| Bredberg, U; Eriksson, UG; Regårdh, CG; Renberg, L; Teger-Nilsson, AC | 1 |
| Andersen, K; Dellborg, M | 1 |
| Hatori, N; Mattsson, C; Nordlander, R; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD | 1 |
| Deinum, J; Nilsson, T; Sjöling-Ericksson, A | 1 |
| Lindfors, L; Sjöström, M; Ungell, AL | 1 |
| Abrahamsson, P; Andersen, K; Clemmensen, P; Dellborg, M; Grande, P; Holmvang, L; Wagner, G | 1 |
| Fischer-Hansen, J; Grip, L; Gundersen, T; Lehto, S; Näslund, U; Wallentin, L | 1 |
| Abrahamsson, P; Andersen, K; Dellborg, M; Nørgaard, BL; Ravkilde, J; Thygesen, K | 1 |
| Van De Werf, F | 1 |
| Egberg, N; Grip, L; Larson, G; Linder, R; Oldgren, J; Siegbahn, A; Wallentin, L | 1 |
| Blombäck, M; Egberg, N; Grip, L; Linder, R | 1 |
| Grip, L; Linder, R; Oldgren, J; Siegbahn, A; Wallentin, L | 2 |
| Bousley, RF; Chi, L; Gallagher, KP; Janiczek, N; Juneau, PL; Mertz, TE; Peng, YW; Rogers, KL; Saganek, L; Uprichard, AC | 1 |
| Elg, M; Gustafsson, D; Mikulski, A | 1 |
| Grip, L; Linder, R; Nørgaard, BL; Oldgren, J; Siegbahn, A; Wallentin, L | 1 |
| Frebelius, S; Jansson, K; Linder, R; Swedenborg, J | 1 |
| Mattsson, C; Nylander, S | 1 |
| Frebelius, S; Grip, L; Linder, R; Swedenborg, J | 1 |
| Grip, L; Linder, R; Oldgren, J; Siegbahn, A; Thygesen, K; Wallentin, L | 1 |
| Frebelius, S; Swedenborg, J; Wahlgren, CM | 1 |
Reviews
2 review(s) available for inogatran and glycine
| Article | Year |
|---|---|
Modulating platelet function with selective thrombin inhibitors.
Topics: Administration, Oral; Adult; Animals; Antithrombins; Arginine; Blood Platelets; Boron Compounds; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Glycine; Hirudin Therapy; Hirudins; Humans; Naphthalenes; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Recombinant Proteins; Sulfonamides; Thrombin | 1996 |
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Topics: Angina, Unstable; Antithrombins; Arginine; Glycine; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Survival Rate; Thrombin | 2002 |
Trials
12 trial(s) available for inogatran and glycine
| Article | Year |
|---|---|
Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.
Topics: Adult; Aged; Angina, Unstable; Antithrombins; Drug Tolerance; Female; Follow-Up Studies; Glycine; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Partial Thromboplastin Time; Piperidines; Recurrence; Thrombin; Vectorcardiography | 1996 |
Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.
Topics: Adult; Aged; Antithrombins; Cohort Studies; Coronary Disease; Female; Glycine; Heparin; Humans; Male; Middle Aged; Multivariate Analysis; Myocardium; Outcome Assessment, Health Care; Piperidines; Prognosis; Prospective Studies; Troponin; Troponin I; Troponin T | 1997 |
A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
Topics: Aged; Angina, Unstable; Antithrombins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycine; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Partial Thromboplastin Time; Piperidines; Time Factors | 1997 |
Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Antithrombins; Double-Blind Method; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Glycine; Heparin; Humans; Male; Middle Aged; Myocardial Ischemia; Piperidines; Prospective Studies; Recurrence; Thrombin; Vectorcardiography | 1998 |
Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease.
Topics: Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Antithrombins; Coronary Disease; Electrocardiography; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Glycine; Heparin; Humans; Hypertension; Male; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Patient Admission; Piperidines; Prognosis; Recurrence; Risk Assessment; Risk Factors; Survival Rate; Vectorcardiography | 1999 |
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points.
Topics: Anticoagulants; Antithrombins; Coronary Disease; Data Collection; Double-Blind Method; Glycine; Heparin; Humans; Multicenter Studies as Topic; Outcome Assessment, Health Care; Piperidines; Randomized Controlled Trials as Topic; Survival Analysis | 1999 |
Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Antithrombins; Coronary Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Glycine; Humans; Male; Middle Aged; Myocardial Infarction; Patient Admission; Piperidines; Prognosis; Prospective Studies; Risk Assessment; Troponin T; Vectorcardiography | 1999 |
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
Topics: Aged; Angina, Unstable; Antithrombins; Biomarkers; Electrocardiography; Enzyme-Linked Immunosorbent Assay; Female; Fibrin; Fibrinolytic Agents; Follow-Up Studies; Glycine; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Partial Thromboplastin Time; Piperidines; Prothrombin; Thrombin; Treatment Outcome | 1999 |
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Antithrombins; Cause of Death; Coronary Disease; Dose-Response Relationship, Drug; Female; Glycine; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Partial Thromboplastin Time; Piperidines; Survival Rate; Thrombin; Treatment Outcome | 1999 |
Coagulation activity and clinical outcome in unstable coronary artery disease.
Topics: Adult; Aged; Angina, Unstable; Anticoagulants; Antithrombin III; Antithrombins; Biomarkers; Blood Coagulation; Female; Fibrin; Fibrin Fibrinogen Degradation Products; Follow-Up Studies; Glycine; Heparin; Humans; Kinetics; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Peptide Hydrolases; Piperidines; Prothrombin; Random Allocation; Treatment Outcome | 2001 |
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; C-Reactive Protein; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Glycine; Humans; Male; Middle Aged; Myocardial Infarction; Myocarditis; Piperidines; Survival Analysis; Troponin T | 2003 |
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Topics: Adult; Aged; Biomarkers; Blood Coagulation; Coronary Artery Disease; Glycine; Heparin; Humans; Middle Aged; Myocardial Ischemia; Piperidines; Predictive Value of Tests; Risk Factors; Thrombin; Thrombophilia; Treatment Failure; Treatment Outcome; Troponin T | 2004 |
Other Studies
21 other study(ies) available for inogatran and glycine
| Article | Year |
|---|---|
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Topics: Animals; Dogs; Female; Glycine; Hemodynamics; Male; Molecular Weight; Piperidines; Thrombin; Thrombosis; Tissue Plasminogen Activator | 1996 |
Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.
Topics: Animals; Aspirin; Coronary Thrombosis; Disease Models, Animal; Female; Glycine; Heparin; Male; Piperidines; Swine; Thrombin | 1996 |
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Aspirin; Bleeding Time; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin; Male; Molecular Weight; Pipecolic Acids; Piperidines; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombolytic Therapy; Thrombophlebitis; Thrombosis | 1996 |
In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor.
Topics: Adenosine Diphosphate; Animals; Antithrombins; Collagen; Dogs; Fibrinolysis; Glycine; Humans; Kinetics; Male; Piperidines; Platelet Aggregation; Rats; Rats, Sprague-Dawley; Serine Endopeptidases; Thrombin; Thrombin Time | 1997 |
Low-molecular weight heparins.
Topics: Angina, Unstable; Animals; Anticoagulants; Antithrombins; Clinical Trials as Topic; Dalteparin; Enoxaparin; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Humans; In Vitro Techniques; Myocardial Infarction; Nadroparin; Piperidines; Thromboembolism | 1997 |
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 1997 |
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Topics: Animals; Azetidines; Benzylamines; Dalteparin; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Infusions, Intravenous; Injections, Intravenous; Male; Piperidines; Rats; Rats, Wistar; Thrombin; Thrombophlebitis; Vena Cava, Inferior | 1997 |
Another chapter of the antithrombin story has been written...
Topics: Acute Disease; Antithrombins; Coronary Disease; Glycine; Heparin; Hirudin Therapy; Humans; Piperidines; Syndrome | 1997 |
BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Topics: Animals; Anticoagulants; Arginine; Arteries; Glycine; Heparin; Hirudins; Humans; Infusions, Intravenous; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombosis; Veins | 1998 |
Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug.
Topics: Animals; Antithrombins; Area Under Curve; Biotransformation; Blood Proteins; Dogs; Female; Glycine; Half-Life; Humans; Macaca fascicularis; Male; Molecular Weight; Piperidines; Rats; Rats, Sprague-Dawley; Species Specificity | 1998 |
Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
Topics: Animals; Antithrombins; Aspirin; Blood Flow Velocity; Coronary Thrombosis; Glycine; Hemodynamics; Heparin; Myocardial Ischemia; Piperidines; Reperfusion Injury; Swine; Thrombolytic Therapy | 1998 |
The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin.
Topics: Antithrombins; Area Under Curve; Arginine; Azetidines; Benzylamines; Binding Sites; Dipeptides; Fluorescence; Glycine; Humans; Kinetics; Molecular Weight; Pipecolic Acids; Piperidines; Spectrometry, Fluorescence; Spectrophotometry; Sulfonamides; Thrombin | 1998 |
Inhibition of binding of an enzymatically stable thrombin inhibitor to lumenal proteases as an additional mechanism of intestinal absorption enhancement.
Topics: Administration, Oral; Animals; Antithrombins; Aprotinin; Biological Availability; Chemistry, Pharmaceutical; Drug Stability; Glycine; Intestinal Absorption; Male; Piperidines; Rats; Rats, Sprague-Dawley; Trypsin Inhibitors | 1999 |
Specific thrombin inhibitors ... only one tool of the antithrombotic armamentarium.
Topics: Antithrombins; Coronary Thrombosis; Drug Therapy, Combination; Glycine; Humans; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Treatment Outcome | 1999 |
Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
Topics: Antithrombins; Dalteparin; Fibrinolytic Agents; Glycine; Heparin; Hirudins; Humans; Intercellular Signaling Peptides and Proteins; Peptides; Pilot Projects; Piperidines; Protein C; Thrombin; Thrombomodulin | 1999 |
Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran.
Topics: Animals; Benzamides; Bleeding Time; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibrinolytic Agents; Glycine; Hemostasis; Implants, Experimental; Injections; Piperidines; Rabbits; Regional Blood Flow; Thrombin; Thrombosis; Vena Cava, Superior | 2001 |
The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats.
Topics: Administration, Oral; Animals; Antithrombins; Azetidines; Benzylamines; Brain Infarction; Cerebral Cortex; Drug Evaluation, Preclinical; Glycine; Hypertension; Injections, Intravenous; Light; Male; Photochemistry; Piperidines; Rats; Rats, Inbred SHR | 2001 |
Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
Topics: Antithrombins; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Endothelium, Vascular; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Piperidines; Protein C; Thrombin; Thrombomodulin | 2003 |
Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action.
Topics: Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Male; P-Selectin; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Receptor, PAR-1; Receptors, Thrombin; Statistics as Topic; Thrombin | 2003 |
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin.
Topics: Amino Acid Chloromethyl Ketones; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Coagulants; Coronary Artery Disease; Fibrinopeptide A; Glycine; Hirudins; Humans; Peptide Fragments; Piperidines; Protein C; Thrombin | 2003 |
Inhibition of neointimal hyperplasia by a specific thrombin inhibitor.
Topics: Animals; Antithrombins; Biomarkers; Disease Models, Animal; Glycine; Hyperplasia; Male; Models, Cardiovascular; Piperidines; Rats; Rats, Sprague-Dawley; Tunica Intima | 2004 |